Intra-immusg Pte Ltd
Clinical trials sponsored by Intra-immusg Pte Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New antibody drug shows promise in fighting advanced cancers Results expected Dec 2026 (estimated)
- New antibody PRL3-Zumab tested against advanced cancers Results expected Dec 2026 (estimated)
- New antibody drug trial offers hope for Hard-to-Treat wet AMD Results expected Feb 2027 (estimated)
-
New antibody drug shows promise in fighting advanced cancers
Disease control OngoingThis Phase 2 trial is testing an experimental drug called PRL3-zumab in 51 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is given as an IV infusion every two weeks. The main goal is to see how long the cancer stays under control and …
Phase 2 • Sponsor: Intra-IMMUSG Pte Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New antibody takes aim at Hard-to-Treat cancers
Disease control OngoingThis Phase 2 trial is testing a drug called PRL3-zumab in 60 people with advanced solid tumors that have not responded to standard treatments. PRL3-zumab is an antibody designed to attach to a protein called PRL3 found on cancer cells, potentially helping the immune system attack…
Phase 2 • Sponsor: Intra-IMMUSG Pte Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC